Rare connective tissue diseases are more common among people with hereditary angioedema (HAE) than in the general population, according…
Articles by Steve Bryson, PhD
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking the approval of donidalorsen as…
A new mutation in the SERPING1 gene was identified as the cause of hereditary angioedema (HAE) in several members of…
The European Commission has granted orphan medicinal product designation (OMPD) to navenibart, an experimental long-acting therapy for hereditary angioedema…
Intellia Therapeutics has launched a Phase 3 clinical trial to evaluate the efficacy and safety of NTLA-2002, a single-dose…
Orladeyo (berotralstat), an approved oral treatment to prevent attacks in hereditary angioedema (HAE) patients 12 years and older,…
People with non-hereditary angioedema living with a substance use disorder (SUD) have a significantly elevated risk of breathing-related hospitalizations…
Changes in the levels of certain metabolites — molecules that take part in metabolism — in the blood may serve…
KalVista Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of sebetralstat,…
Treatment with oral Orladeyo (berotralstat) led to significantly fewer disease-related or all-cause hospitalizations and emergency room visits by people…